In first for EU, anti-skin cancer drug approved

PARIS: French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU.

The tumour-reducing drug is aimed at patients with the second-most common form of skin cancer - cutaneous squamous cell carcinoma - whose cancer is advanced, and who are not candidates for surgery or radiation therapy.

"The benefits with Libtayo are its ability to reduce tumour size and to prevent progression of the tumour for longer," it said.Final approval of the drug will be given subject to Sanofi providing further results from clinical trials.The US Food and Drug Administration approved Libtayo in September 2018 while Health Canada gave it the conditional green light earlier this month.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

In north Syria, skin disease ravages young and oldInside a dank clinic in the north of war-torn Syria, a girl covered in scabs wails and tries to wriggle out of her mother's arms to escape a nurse's needle. The illness is endemic to Syria, the World Health Organisation (WHO) says, but has become more prevalent during the eight-year civil war
Source: YahooSG - 🏆 3. / 71 Read more »

MOH announces cut in overseas registered schools approved for practice in SingaporeThe Singapore Medical Council (SMC) has reviewed the list, and proposed that the number of overseas medical schools with basic medical qualifications be reduced from 160 to 103, effective Jan 1 2020.
Source: IndependentSG - 🏆 2. / 72 Read more »